Previous Article | Next Article ![]()
Journal of Clinical Microbiology, July 2009, p. 2149-2155, Vol. 47, No. 7
0095-1137/09/$08.00+0 doi:10.1128/JCM.00027-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Instituto de Microbiologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil,1 Instituto de Pesquisa Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil,2 Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo, São Paulo, Brazil,3 Sérgio Franco Medicina Diagnóstica, Rio de Janeiro, Brazil,4 Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil,5 Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil,6 Secretaria de Vigilância em Saúde do Ministério da Saúde, Brasília, Brazil,7 Instituto de Estudos de Saúde Coletiva, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil,8 Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil,9 Hospital de Clínicas Riomar, Rio de Janeiro, Brazi1,10 Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazi1,11 Centro de Referência Professor Hélio Fraga, Rio de Janeiro, Brazil,12 Instituto Fleury de Ensino e Pesquisa, São Paulo, Brazil,13
Received 6 January 2009/ Returned for modification 19 February 2009/ Accepted 4 April 2009
|
|
|---|
32 µg/ml), cefoxitin (MIC90, 128 µg/ml), and doxycycline (MIC90,
64 µg/ml). Representative epidemic M. massiliense isolates that were randomly selected, including at least one isolate from each hospital where confirmed cases were detected, belonged to a single clone, as indicated by the analysis of pulsed-field gel electrophoresis (PFGE) patterns. They also had the same PFGE pattern as that previously observed in two outbreaks that occurred in other Brazilian cities; we designated this clone BRA100. All five BRA100 M. massiliense isolates tested presented consistent tolerance to 2% glutaraldehyde. This is the largest epidemic of postsurgical infections caused by RGM reported in the literature to date in Brazil. |
|
|---|
Outbreaks of RGM infections unrelated to medical procedures also can occur and usually are associated with exposure to recreational water containing a large number of bacteria and inadequate chlorination (15, 44), highlighting the ubiquity of these organisms in the environment. In fact, RGM have been recovered from many different environmental sources, including soil and water distribution systems (8, 45). RGM are considered opportunistic pathogens and can cause chronic lung disease, particularly the species included in the M. chelonae-M. abscessus group (8, 46).
M. chelonae-M. abscessus group taxonomy has undergone several updates due to the discrimination of new species by sequencing multiple housekeeping genes and, to a lesser extent, by the evaluation of phenotypic characteristics. Mycobacterium bolletii and Mycobacterium massiliense are newly proposed species that are closely related to M. abscessus and M. chelonae, and consequently they should be considered part of the same group (1, 4). The species M. massiliense was proposed in 2004 based on nonconventional phenotypic characterization and genotypic studies of two isolates recovered from sputum and bronchoalveolar fluid from a patient in Marseille, France (4). Following the original description, reports from different areas of the world have described the occurrence of this species both in culture collections previously classified as M. abscessus and as the cause of invasive opportunistic infections and outbreaks (9, 18, 34, 38, 40).
In Brazil, outbreaks caused by RGM have been detected since 1998, mainly in the cities of Rio de Janeiro and São Paulo. Eight outbreaks following laser in situ keratomileusis (surgery for myopia correction), mesotherapy sessions (intradermal injections), or breast implants have been described, most of them associated with species belonging to the M. chelonae-M. abscessus group. (16, 30-32). Recently, two outbreaks of surgical-site infection following video-assisted surgeries were reported in Brazil (9, 40).
Since August 2006, a large number of surgical wound infections caused by RGM following video-assisted surgery have been diagnosed in the state of Rio de Janeiro, in the southeast region of Brazil. From August 2006 to July 2007, more than 1,000 suspected cases were reported to the Secretary of Health of the Rio de Janeiro state.
The aim of this work was to define species identification, antimicrobial and glutaraldehyde susceptibility patterns, and the clonality of representative mycobacterial isolates recovered from postsurgery wound infections during the epidemic.
|
|
|---|
Primary isolation of mycobacteria from clinical samples. Tissue fragments and secretions were obtained after biopsy or needle aspiration procedures, respectively, and processed for baciloscopy and culture at local clinical laboratories (24). These were inoculated onto 5% sheep blood agar and chocolate agar, Lowenstein-Jensen (LJ) slants, and in some laboratories, also in mycobacteria growth indicator tube (MGIT) broth (Becton-Dickinson, Franklin Lakes, NJ).
Phenotypic tests. All isolates were tested for growth rate, pigment production, and acid fastness as described elsewhere (24).
Outbreak strains, unrelated controls, and environmental isolate. RGM strains from previously reported outbreaks of surgical wound infections that occurred in Brazil in Belém city (F1832) and Goiânia city (F1334 and F1345), one epidemiologically unrelated isolate (CRM-0270), and the M. massiliense type strain CIP108297 were used as unrelated controls. The isolate CRM-0270 was recovered in 2007 from a sputum sample collected from a patient who lived in the city of Rio de Janeiro who had not previously submitted to bronchoscopy. One isolate (CRM-0029), recovered from a trocar used in a cholecystectomy performed in hospital H18 during the epidemic period, also was included for comparison purposes.
PRA-hsp65. All 146 isolates were analyzed initially using the PCR-restriction enzyme analysis of the hsp65 gene (PRA-hsp65), as previously described by Telenti et al. (36) and Ringuet et al. (28), with minor modifications. In brief, a loopfull of recent growth on LJ was suspended in 70 µl of 1x Tris-EDTA (TE), boiled for 10 min, and frozen at –20°C. Amplification was carried out with the primers Tb11 (5'-ACC AAC GAT GGT GTG TCC AT-3') and Tb12 (5'-CTT GTC GAA CCG CAT ACC CT-3'). The PCR mixture consisted of 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 1% formamide, 200 µM each deoxynucleoside triphosphate (dNTP), 0.5 µM primers, 1.25 U Platinum Taq polymerase (Invitrogen Life Technologies Brazil, São Paulo, Brazil), and 5 µl of bacterial lysate. Amplification was achieved with a GeneAmp PCR system 2400 (Perkin-Elmer, Branchburg, NJ) under the following conditions: 45 cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min, with a final extension step at 72°C for 10 min. Amplicons were digested with either BstEII (Promega Corporation, Madison, WI) or HaeIII (Promega); restriction fragments were analyzed after 3% FingerPrinting agarose gel (BioAmerica Inc., Miami, FL) electrophoresis and staining with ethidium bromide. Fifty- and 25-bp DNA ladders (Promega) were used as reference standards.
Species identification by DNA sequencing. At least one randomly selected isolate from each of the 38 hospitals (74 isolates), as well as the isolate recovered from the trocar, the unrelated strain, and isolates that presented distinct PRA-hsp65 patterns were analyzed by the partial sequencing of the hsp65 and/or rpoB genes, as previously described (2, 33).
Partial sequencing of the hsp65 gene. Primers hsp667FW (5'-GGCCAAGACAATTGCGTACG-3') and hsp667RV (5'-GGAGCTGACCAGCAGGATG-3') were used to amplify and sequence a 667-bp region containing Telenti's fragment (positions 145 to 585 of the M. tuberculosis H37Rv genome) of the hsp65 gene. A total of 5 µl of each DNA solution (50 µg/ml) was added to 45 µl of a PCR mixture containing 50 mM KCl, 20 mM Tris-HCl (pH 8.4), 1.5 mM MgCl2, 1% enhancer (Invitrogen), 200 µM each dNTP, 1 µM primers, and 1.25 U of Platinum Taq DNA polymerase (Invitrogen). Amplification conditions were 2 min at 95°C, followed by 30 cycles of 94°C for 45 s, 57°C for 45 s, and 72°C for 45 s, with a final extension step of 72°C for 5 min. Sequencing was performed as described below.
Partial sequencing of the rpoB gene. A 764-bp fragment was amplified and sequenced with primers MycoF (5'-GCAAGGTCACCCCGAAGGG-3') and MycoR (5'-AGCGGCTGCTGGGTGATCATC-3'). A total of 5 µl of each DNA solution (50 µg/ml) was added to 45 µl of a PCR mixture containing 50 mM KCl, 20 mM Tris-HCl (pH 8.4), 2.5 mM MgCl2, 200 µM each dNTP, 1 µM primers, and 1.0 U of Taq DNA polymerase (Promega). PCR mixtures were heated at 95°C for 1 min and then subjected to 35 cycles of denaturation at 94°C for 30 s, annealing at 64°C for 30 s, and extension at 72°C for 90 s, with a final step of 72°C for 5 min. Amplicons were purified with GFX PCR DNA and a Gel Band purification kit (G&E) and sequenced in an ABI PRISM 3100 sequencer with a BigDye Terminator cycle sequencing kit (Applied Biosystems). The sequences obtained were compared with those deposited in the GenBank database by using BLAST (http://www.ncbi.nlm.nih.gov/BLAST).
Antimicrobial susceptibility testing. A total of 74 M. massiliense epidemic isolates, including at least one from each hospital, previously identified to the species level by hsp65 or rpoB gene sequencing were evaluated for their susceptibility to amikacin, ciprofloxacin, cefoxitin, clarithromycin, and doxycycline as recommended by the Clinical and Laboratory Standards Institute (10). Staphylococcus aureus ATCC 29213 was used as a quality control strain.
Genomic restriction endonuclease digestion and PFGE. A total of 65 representative isolates, including at least one isolate from each of the 38 hospitals that had confirmed cases, isolates from previous M. massiliense outbreaks (F1345 and F1832), and epidemiologically unrelated isolates (CRM-0270 and M. massiliense type strain CIP108297) were analyzed by pulsed-field gel electrophoresis (PFGE). Bacterial suspensions were included in agarose plugs, treated as described by Coleman et al. (11) and Sampaio et al. (32), and finally digested with DraI (Promega). Restriction fragments were separated by PFGE in 1% agarose gels in a CHEF-DRIII system (Bio-Rad) with pulse times increasing from 1.6 to 21.3 s for 22 h at 14°C, with a voltage gradient of 6 V/cm. The restriction profiles were analyzed and compared using the Molecular Analyst Fingerprinting Plus software package, version 1.12, of the Image Analysis System (Bio-Rad). The interpretative criteria applied were those proposed by Tenover et al. (37).
Glutaraldehyde tolerance. Five randomly selected isolates obtained from patients from hospitals H28 (CRM 0018, CRM 0019, and CRM 0020) and H34 (CRM 0034 and CRM 0035) belonging to the clonal group BRA100, as well as two unrelated isolates cultivated from sputum samples (CRM 0270 and CRM 0273), were evaluated concerning their ability to survive after 30 min or 10 h of exposure to 2% commercial glutaraldehyde solutions using the suspension method, as recommended by the manufacturers for high-level disinfection and sterilization (6, 12). Each assay was repeated three times and also included Mycobacterium smegmatis PRD no.1 00061, Mycobacterium bovis INCQS 00062, M. abscessus ATCC 19977, and M. chelonae ATCC 35752 strains as quality control strains. Mycobacterial suspensions with a turbidity equivalent to a McFarland 1 standard were prepared from cultures that had been grown on LJ medium for no more than 7 days. Five hundred microliters was added to 4.5 ml of each activated glutaraldehyde solution and incubated at 25°C. After 30 min and 10 h, an aliquot of 0.5 ml of each mixture containing bacteria and glutaraldehyde was transferred to a new vial containing the same volume of 1% sodium sulfite (1:1, vol/vol). They were mixed, seeded on LJ slants, and incubated at 35°C in ambient air for 60 days.
Nucleotide sequence accession numbers. The GenBank database accession numbers generated in this study are EU009467.1, EU009468.1 EU009469.1, FJ515915.1, FJ515916.1, FJ516384.1, FJ516386.1, FJ531482.1, FJ531483.1, and FJ531484.1.
|
|
|---|
![]() View larger version (44K): [in a new window] |
FIG. 1. Distribution of positive laboratory tests among 302 probable cases with notified laboratory diagnosis during the epidemic of RGM postsurgical infections in Rio de Janeiro, Brazil (2006 to 2007).
|
Commercial 2% glutaraldehyde solution was used for the disinfection of the surgical instruments (15 to 30 min of exposure) in all institutions that had confirmed cases. At least 58 different surgeons reported suspected cases during the epidemic period. From April 2008, no more cases have been reported in the state of Rio de Janeiro. The decrease in the number of cases was observed either after the discontinuation of the use of 2% glutaraldehyde solution in high-level disinfection or during temporary interruptions of surgeries until the resolution of epidemics at some care centers. No surveillance studies were performed for mycobacterial isolation from medical devices. No public health measures were suggested or implemented by local authorities before September 2008.
Species identification. A total of 148 acid-fast-positive isolates were recovered from clinical samples and available for further characterization. Most of them (n = 144; 97.2%) were nonpigmented rapid growers, with a PRA-hsp65 pattern compatible with that of M. massiliense or M. bolletii (PRA-MmMb), with BstEII restriction fragments of 235 and 210 bp and HaeIII restriction fragments of 200, 70, 60, 50, and 40 bp (Fig. 2). All isolates with the PRA-hsp65 pattern PRA-MmMb submitted to sequencing (n = 74) had identical rpoB sequences. Such sequences (GenBank accession numbers EU009467.1, EU009468.1, and EU009469.1) are 99.71% (686/688) similar to those of the M. massiliense type strain CIP 108297 (EU254721.1 and AY593981.2). These two substitutions, located at positions 2563 and 2754 of rpoB from M. tuberculosis H37Rv (GenBank accession BX842574.1), are silent, since the amino acid sequences are identical. Two (1.3%) nonpigmented, rapidly growing isolates presented identical PRA-hsp65 patterns, with BstEII fragments of 230, 125, and 80 bp and HaeIII fragments of 145, 120, 60, and 40 bp, which match the patterns of the Mycobacterium fortuitum group. One of these isolates (CRM-0264) had hsp65 and rpoB partial sequences that were identical to those of accession numbers AY458072.1 and AY147165.1, respectively, which belong to the type strain of M. fortuitum CIP104534. The second isolate (CRM-0267) had hsp65 (GenBank accession no. FJ531484.1) and rpoB (GenBank accession no. FJ531483.1) partial sequences that were 100% (424/424) and 99.56% (694/697) similar to GenBank accession numbers AY458064.1 and AY262743.2, respectively, which correspond to the Mycobacterium wolinskyi type strain ATCC700010. The two yellow-pigmented scotochromogenic isolates F1672 and F1694 had hsp65 partial sequences (GenBank accession numbers FJ515915.1 and FJ515916.1) that had the highest similarity indexes (99.8% [423/424] and 99.5% [422/424], respectively) compared to the hsp65 sequence of the Mycobacterium neoaurum type strain CIP 105387 (GenBank accession no. AF547860.1). Each of these M. neoaurum isolates were recovered together with M. massiliense colonies from two patients with mixed mycobacterial infection.
![]() View larger version (69K): [in a new window] |
FIG. 2. PRA-hsp65 profiles of six representative M. massiliense epidemic isolates. Lanes 1 and 15, 50-bp DNA ladder; lane 8, 25-bp DNA ladder; lanes 2 to 7, amplicons digested with BstEII; lanes 9 to 14, amplicons digested with HaeIII. Each lane represents a different strain: lane 2, CRM-0006; 3, CRM-0018; 4, CRM-0029; 5, CRM-0181; 6, CRM-0189; 7, CRM-0195; 9, CRM-0006; 10, CRM-0018; 11, CRM-0029; 12, CRM-0181; 13, CRM-0189; and 14, CRM-0195.
|
M. massiliense isolates from the outbreaks that occurred in the cities of Goiânia (F1345 and F1334; GenBank accession nos. EU031904.1 and EU031905.1) and Belém (F1832; GenBank accession no. FJ531482.1) had the same rpoB sequence as those described for the isolates from Rio de Janeiro.
Antimicrobial susceptibility. All 74 isolates tested were susceptible to amikacin (MIC at which 90% of the tested isolates are inhibited [MIC90], 8 µg/ml) and clarithromycin (MIC90, 0.25 µg/ml) but resistant to ciprofloxacin and doxycycline. Cefoxitin MICs were high for most isolates (Table 1).
|
View this table: [in a new window] |
TABLE 1. Antimicrobial susceptibility of 74 RGM M. massiliense epidemic isolates recovered from wound infections after video laparoscopic surgery during an outbreak in Rio de Janeiro, Brazil (2006 to 2007)
|
![]() View larger version (111K): [in a new window] |
FIG. 3. PFGE profiles of genomic DNA from M. massiliense isolates after digestion with DraI. Lanes 1 and 15, molecular size markers (Lambda DNA concatemers ranging from 48.5 to 1,018.5 kb); 2, CRM-0006; 3, CRM-0013; 4, CRM-0018; 5, CRM-0019; 6, CRM-0020; 7, CRM-0029; 8, CRM-0169, 9, CRM-0172; 10, CRM-0181; 11, CRM-0185; 12, CRM-0189; 13, CRM-0191; and 14, CRM-0195.
|
![]() View larger version (36K): [in a new window] |
FIG. 4. Dendrogram resulting from computer-assisted analysis of the PFGE profiles of 43 representative M. massiliense isolates. The Dice coefficient was used for calculating the percentages of similarity among the profiles. M. massiliense isolates recovered during outbreaks in other Brazilian cities are marked in bold. Diag., diagnosis. Footnotes: a, the mycobacterial isolate was recovered from a patient who submitted to video laparoscopic surgery headed by the Dr.n team; b, the mycobacterial isolate was obtained from a patient who submitted to surgery at hospital (H) n; c, RJ, Rio de Janeiro city; d, NR, not reported; e, NA, not applicable.
|
|
|
|---|
Our work, as with the two previous reports of M. massiliense outbreaks, has a limitation; namely, the small number of unrelated strains and the unknown discriminatory power of PFGE for this bacterial species. M. massiliense has phenotypic and genotypic characteristics that are very similar to those of M. abscessus. Although Adékambi et al. described some phenotypic tests (nitrate reductase, β-glucuronidase, β-galactosidase, N-acetyl-β-glucosaminidase, and indole production) that could differentiate these species, their conclusions were based on two isolates and should not be applied to clinical laboratories before validation with a large collection of unrelated isolates (4). Although there is not a consensus on the best target for mycobacterial species discrimination, the partial sequencing of hsp65 and/or rpoB genes has been used to differentiate RGM species (2). Currently, species that have a similarity index equal to or less than 98.1% for the rpoB fragment, as proposed by Adékambi et al. (3), should be considered different. In this work, we obtained the highest similarity index (99.7%) for the comparison of our sequences to those of the M. massiliense type strain. The hsp65 partial sequence of the epidemic isolates had 100% similarity to that of the M. massiliense type strain, while the minimal similarity index for the same species has been proposed as
97% (21). These data indicate that under the current classification of mycobacteria, the epidemic was caused by M. massiliense.
In this report, all of the M. massiliense isolates tested were susceptible to amikacin and clarithromycin but resistant to cefoxitin, ciprofloxacin, and doxycycline. Our results are in accordance with those reported by Adékambi et al. (4), except that the doxycycline MICs for our isolates was higher, which is in agreement with results reported by other authors (34, 40). This evidence reinforces that susceptibility to doxycycline cannot be used as a marker for differentiation between M. abscessus and M. massiliense.
In summary, to our knowledge, this report describes the largest surgical-site infection epidemic caused by a unique clone of M. massiliense reported to date and reinforces the risk of using 2% glutaraldehyde solution for disinfecting surgical devices.
The Instituto Nacional de Controle de Qualidade em Saúde (INCQS/FIOCRUZ) is acknowledged for providing Mycobacterium smegmatis PRD no.1 00061 and Mycobacterium bovis INCQS 00062 strains.
This study was supported in part by the Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ; processes no. 110.347/2007 and 18123/2008), the Conselho Nacional de Desenvolvimento Científico e Tecnológico (MCT/CNPq; Edital Universal, process no. MCT/CNPq-no. 15/2007), and PDTIS-FIOCRUZ.
Published ahead of print on 29 April 2009. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»